AptarGroup Completes Acquisition of Majority Stake in Voluntis (Theraxium Digital Therapeutics)

Zentiva Completes Voluntary Public Purchase Offer for APONTIS PHARMA AG

December 9, 2024

Pharmaceuticals

Zentiva has completed its voluntary public purchase offer for the shares of APONTIS PHARMA AG. Following settlement, Zentiva holds approximately 83.57% of the share capital and approximately 85.27% of the voting rights, with management agreeing to terminate the shares’ inclusion in trading on the Freiverkehr immediately after settlement.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.

Vividion Therapeutics Acquires Tavros Therapeutics

January 12, 2025

Biotechnology

Vividion Therapeutics, a wholly owned subsidiary of Bayer AG, has acquired precision oncology platform company Tavros Therapeutics. The acquisition expands Vividion’s functional genomics and genomic screening capabilities, combining Tavros’s platform with Vividion’s chemoproteomics expertise to accelerate discovery of novel targets in oncology and immunology; financial terms were not disclosed.

Thoma Bravo Acquires Majority Interest in Apttus

September 4, 2018

Software

Thoma Bravo signed a definitive agreement to acquire a majority interest in Apttus, a San Mateo–based provider of Quote-to-Cash, Contract Lifecycle Management and Middle Office software. The deal (expected to close in early October 2018) will pair Apttus’ enterprise revenue-management platform with Thoma Bravo’s software operating experience to accelerate growth and scale; financial and legal advisors and financing partners were disclosed but financial terms were not.

Pharmaron Acquires 82.54% of Biortus Biosciences

October 28, 2025

Healthcare Services

Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.

Volaris Group Acquires medaptus

November 17, 2020

Software

Volaris Group, an operating group of Constellation Software Inc., has acquired medaptus, a Boston-based healthcare IT software company. The acquisition expands Volaris’ healthcare software portfolio by adding medaptus’ revenue cycle, patient assignment, and throughput automation solutions to its vertical market offerings.